Corvus Pharmaceuticals, Inc. (CRVS)
After hours:
| Previous close | 5.13 |
| Open | 5.20 |
| Bid | 5.08 x 500 |
| Ask | 5.15 x 400 |
| Day's range | 4.96 - 5.22 |
| 52-week range | 1.05 - 5.22 |
| Volume | |
| Avg. volume | 319,893 |
| Market cap | 319.012M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical
- GlobeNewswire
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company’s presenta
- GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma (PTCL) Advancing Toward Initial Enrollment in Q3 2024; New Complete Response Achieved in Ongoing Phase 1/1b Clinical Trial Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE)
